Sunlenca lenacapavir

Drug Class

HIV-1 capsid inhibitor

Mechanism

Inhibits HIV-1 replication by binding directly to the capsid protein, thereby interfering with capsid-mediated nuclear import, virion assembly and release, and capsid disassembly.

Approved Indication

Treatment of HIV-1 infection, in combination with other antiretroviral(s), in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.

What This Means For Patients

Sunlenca is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2022) — Sources
• EMA — Approved (2022) — Sources
• NMPA — Approved (2025) — Sources

Pivotal Clinical Evidence

• CAPELLA — Segal-Maurer et al., N Engl J Med 2022 (NCT04150068) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca
• https://www.nmpa.gov.cn/